References
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. LANCET. 2020 Jan 24;395:497–506.
- Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–1207.
- Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol. 2020 Jan 16;92(4):401–402.
- Lillie PJ, Samson A, Li A, et al. Novel coronavirus disease (Covid-19): the first two patients in the UK with person to person transmission. J Infect. 2020 Feb 28;80:578–606. .
- Spina S, Marrazzo F, Migliari M, et al. The response of Milan’s emergency medical system to the COVID-19 outbreak in Italy. LANCET. 2020 Feb 28;395:e49-e50. .
- Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11:222.
- Kim UJ, Won EJ, Kee SJ, et al. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for middle east respiratory syndrome. Antivir Ther. 2016;21(5):455–459.
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787–1799.
- Lyu P, Chen FF. National HIV/AIDS epidemic estimation and interpretation in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2019;40(10):1191–1196.
- Update on COVID-19 as of 1 September. National Health Commission of the People’s Republic of China; 2020 cited 2020 Sep 02. Available from: http://www.nhc.gov.cn/xcs/yqfkdt/202009/c9e6ec635c2447a7a467934b1b98aa7a.shtml
- National Institute for Viral Disease Control and Prevention (China). Specific primers and probes for detection 2019 novel coronavirus. Beijing: National Institute for Viral Disease Control and Prevention (China); [ Chinese]. 2020 Jan 21. Available from http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html
- Zhu F, Cao Y, Xu S, et al. Co‐infection of SARS‐CoV‐2 and HIV in a patient in Wuhan city, China. J Med Virol. 2020;92(6):529–530.
- Blanco JL, Ambrosioni J, Garcia F, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020;7(5):e314–e316.
- Guo W, Ming FZ, Feng Y, et al. Patterns of HIV and SARS-CoV-2 co-infection in Wuhan, China. J Int AIDS Soc. 2020;23:e25568.
- Zhao JJ, Liao XJ, Wang HY, et al. Early virus clearance and delayed antibody response in a case of COVID-19 with a history of co-infection with HIV-1 and HCV. Clin Infect Dis. 2020 Apr 9:ciaa408. Online ahead of print. DOI: 10.1093/cid/ciaa408
- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. published online Feb 7. DOI:10.1001/jama.2020.1585.
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
- Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020;221:1762–1769.
- Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: A randomized controlled trial. JAMA. 2011;305:1432–1440.
- De Vries-Sluijs TE, Hansen BE, van Doornum GJ, et al. A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. J Infect Dis. 2011;203:984–991.
- Chaiklang K, Wipasa J, Chaiwarith R, et al. Comparison of immunogenicity and safety of four doses and four double doses vs. Standard doses of hepatitis B vaccination in HIV-infected adults: A randomized, controlled trial. PLoS One. 2013;8:e80409.
- Psevdos G, Kim JH, Groce V, et al. Efficacy of double-dose hepatitis B rescue vaccination in HIV-infected patients. AIDS Patient Care STDS. 2010;24(7):403–407. .
- Sayad B, Alavian SM, Najafi F, et al. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in HIV/AIDS patients: a randomized controlled trial. Hepat Mon. 2012;12(9):e6234. .
- Costenaro P, Minotti C, Barbieri E, et al. SARS-CoV-2 infection in people living with HIV: a systematic review. Rev Med Virol. 2020 Sep 1:e2155. Online ahead of print. DOI: 10.1002/rmv.2155